Biopharma firm CorMedix's preliminary Q3 revenue beats estimates, raises FY guidance

CorMedix

20/10/2025 12:39

Corrects syntax in headline and revenue figure in Key Details table to $125 mln, from $85 mln

Overview

CorMedix's preliminary Q3 2025 revenue beats expectations, driven by strong DefenCath utilization

Company raises FY 2025 revenue guidance to at least $375 mln

CorMedix expects $30 mln operating synergy before year-end 2025

Outlook

CorMedix raises FY 2025 pro forma net revenue guidance to at least $375 mln

Company expects $30 mln in synergies by end of 2025

CorMedix projects year-end cash balance of approximately $100 mln

Result Drivers

DEFENCATH UTILIZATION - Stronger than expected utilization of DefenCath drove revenue growth

MELINTA INTEGRATION - Integration of Melinta portfolio contributed to increased revenue guidance

COST SYNERGIES - Significant progress on Melinta integration with expected cost synergies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$125 mln
$66.13 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for CorMedix Inc is $20.50, about 50.3% above its October 17 closing price of $10.18

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nGNX1Hlv0s

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)